van der Eerden Menno M, de Graaff Casper S, Vlaspolder Fer, Bronsveld Willem, Jansen Henk M, Boersma Wim G
Department of Pulmonary Diseases Medical Center Alkmaar, Alkmaar, The Netherland.
Clin Ther. 2004 Feb;26(2):294-303. doi: 10.1016/s0149-2918(04)90028-8.
In patients with community-acquired pneumonia (CAP), switching from IV to PO antibiotics offers advantages over IV therapy alone, including improved cost-effectiveness through reductions in the length of hospital stay and treatment costs.
The aim of this study was to determine whether a method for switching therapy in clinical practice could be used in patients with CAP and whether differences were found in the duration of IV treatment and length of hospital stay between the 5 risk classes of the Pneumonia Severity Index (PSI) after the therapy switch.
This was a prospective, observational study of patients aged >/=18 years presenting with CAP at our teaching hospital between December 1998 and November 2000. Microbiological and serological tests were performed, and signs and symptoms of CAP, C-reactive protein levels, and white blood cell counts were assessed throughout treatment and at the 1-month follow-up. Patients were stratified by PSI risk class. When the patient's temperature had been normalized for 72 hours and respiratory symptoms (dyspnea, coughing, and thoracal pain) had improved, patients were switched from IV to PO therapy (same drug).
The study included 180 patients with CAP Clinical cure was seen in 174 (97%) patients. No significant difference between the 5 risk classes was found in duration of therapy. Patients in risk class V remained hospitalized for a significantly longer period than patients in risk classes I through IV (P < 0.001). Furthermore, after patients were switched to PO antibiotics, the level of C-reactive protein decreased in patients in all risk classes and was normalized by follow-up.
In the population studied, use of specific criteria (ie, absence of fever for 72 hours and reduction in respiratory symptoms) allowed successful switch from IV to PO antibiotic therapy for the treatment of CAP Duration of therapy was not affected by PSI risk class, but those in risk class V were hospitalized longer than other risk classes.
在社区获得性肺炎(CAP)患者中,从静脉注射抗生素转换为口服抗生素比单纯静脉治疗具有优势,包括通过缩短住院时间和降低治疗成本提高成本效益。
本研究的目的是确定临床实践中的一种转换治疗方法是否可用于CAP患者,以及在治疗转换后,肺炎严重程度指数(PSI)的5个风险类别之间的静脉治疗持续时间和住院时间是否存在差异。
这是一项对1998年12月至2000年11月在我们教学医院就诊的年龄≥18岁的CAP患者进行的前瞻性观察研究。进行了微生物学和血清学检测,并在整个治疗过程和1个月随访时评估CAP的体征和症状、C反应蛋白水平和白细胞计数。患者按PSI风险类别分层。当患者体温正常72小时且呼吸症状(呼吸困难、咳嗽和胸痛)改善时,患者从静脉治疗转换为口服治疗(使用相同药物)。
该研究纳入了180例CAP患者。174例(97%)患者实现临床治愈。各风险类别之间的治疗持续时间无显著差异。V类风险患者的住院时间明显长于I至IV类风险患者(P<0.001)。此外,患者转换为口服抗生素后,所有风险类别的患者C反应蛋白水平均下降,并在随访时恢复正常。
在所研究的人群中,使用特定标准(即72小时无发热和呼吸症状减轻)可成功将治疗从静脉注射抗生素转换为口服抗生素以治疗CAP。治疗持续时间不受PSI风险类别的影响,但V类风险患者的住院时间比其他风险类别更长。